March 3, 2022

New results from the RECOVERY trial – baricitinib

Since March 2020, the University of Oxford-led RECOVERY trial has been testing a range of potential treatments for patients hospitalised with COVID-19, and have found three treatments which benefit patients.

Baricitinib, an anti-inflammatory treatment normally used to treat rheumatoid arthritis, was added to the trial in February 2021.

The team now have their results on baricitinib. Journalists dialled in to this press briefing to hear the Chief Investigators of the trial describe and explain their results.

Please note this data is a preprint, so it is early work that has not yet been through peer-review and is not published in a journal.

Speakers included:

Prof Sir Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, University of Oxford, and Joint Chief Investigator of the RECOVERY trial

Prof Sir Martin Landray, Professor of Medicine and Epidemiology at the Nuffield Department of Population Health, University of Oxford, and Joint Chief Investigator of the RECOVERY trial

This Briefing was accompanied by an SMC Roundup of Comments.